Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07479550 · ClinicalTrials.gov registry record · Phase 2
Study of Psilocybin Under Anesthesia Controlled by EEG
A Phase 2 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT07479550: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT07479550 is a Phase 2 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07479550, a Phase 2 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Major depressive disorder (MDD) affects millions of Americans and remains difficult to treat. Psilocybin, a psychedelic compound, has shown promise for reducing depression symptoms, but a key challenge in psychedelic research is that participants can usually tell whether they received the active drug - making it hard to conduct fully blinded studies. This study (Studying Psilocybin with Anesthesia Controlled by EEG \[SPACE\]) tests a new approach: administering psilocybin while participants are under general anesthesia, so that the noticeable psychological effects of psilocybin are masked. This allows both participants and outcome assessors to remain unaware of whether psilocybin or placebo was given, improving the scientific rigor of the research. Participants with MDD will be randomly assigned to receive either psilocybin or placebo across four dosing sessions conducted under general anesthesia. The study will assess whether this approach is safe and feasible, and will collect early data on whether it may reduce depression symptoms.
Primary Outcome
Percentage of participants who correctly guess whether they received a full dose of psilocybin during the final dosing session (Visit 20), assessed using the Blinding Survey at Visit 21.
Interventions
- DRUG Placebo
- DRUG Propofol
- DRUG Psilocybin (Usona Institute)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-07 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
What is known before NCT07479550 opens enrollment
NCT07479550 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07479550 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07479550 about?
NCT07479550 is a clinical study titled "Study of Psilocybin Under Anesthesia Controlled by EEG". Major depressive disorder (MDD) affects millions of Americans and remains difficult to treat. Psilocybin, a psychedelic compound, has shown promise for reducing depression symptoms, but a key challenge in psychedelic research is that participants can usually tell whether they received the active dru...
What is the current status of trial NCT07479550?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2026-07. Estimated completion is 2027-08.
What interventions are being tested in trial NCT07479550?
The interventions under investigation include: Placebo (DRUG), Propofol (DRUG), Psilocybin (Usona Institute) (DRUG).
Who is sponsoring clinical trial NCT07479550?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07479550's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia